Finance
Novo Holdings' $16.5 billion Catalent buy wins EU antitrust approval
Published by Global Banking & Finance Review®
Posted on December 6, 2024
1 min readLast updated: January 27, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on December 6, 2024
1 min readLast updated: January 27, 2026
Novo Holdings' $16.5 billion acquisition of Catalent receives EU antitrust approval, with no competition concerns in the EEA.
By Foo Yun Chee
BRUSSELS (Reuters) - Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, which makes the blockbuster weight-loss drug Wegovy, had announced the deal in February.
"The proposed merger would not raise competition concerns on any of the markets examined in the EEA (European Economic Area) or on any substantial part of it," the European Commission said in a statement, confirming a Reuters story.
The EEA refers to the 27 EU countries, Iceland, Liechtenstein and Norway.
The EU antitrust watchdog said there are sufficient competing alternatives in the market.
Soaring sales of Wegovy have made Novo Nordisk Europe's most valuable company by market value.
(Reporting by Foo Yun Chee, additional reporting by Ludwig Burger in Frankfurt)
The main topic is Novo Holdings' acquisition of Catalent and its approval by EU antitrust regulators.
The EU approved the acquisition as there were no competition concerns in the European Economic Area.
Wegovy's soaring sales have significantly increased Novo Nordisk's market value, making it Europe's most valuable company.
Explore more articles in the Finance category
